1
|
Liu Y, Yu Z, Sun H. Treatment Effect of Type 2 Diabetes Patients in Outpatient Department Based on Blockchain Electronic Mobile Medical App. J Healthc Eng 2021; 2021:6693810. [PMID: 33728034 DOI: 10.1155/2021/6693810] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 01/21/2021] [Accepted: 02/18/2021] [Indexed: 12/13/2022]
Abstract
As the pace of people's lives accelerates, there are more and more diabetic patients. This research mainly explores the treatment effect of type 2 diabetic patients based on blockchain electronic mobile medical app. Considering that it is more realistic to adopt an off-chain storage solution, the blockchain-based medical data sharing platform in this study adopts an off-chain storage solution. Only key information is stored in the blockchain network, and all medical data will be in the cloud space. For storage, cloud storage uses Aliyun's OSS storage service, which can be expanded infinitely. The cloud operation module is responsible for all operations that interact with cloud storage. The chain code can call the cloud operation module to upload the user's encrypted medical data and user ID to Alibaba Cloud's OSS. The chain code will return the storage address of the medical data and the authorized access address is sent to the blockchain network for consensus on the chain. The message processing module provides information processing functions such as chat information processing, APP use reminders, and health tips. The indicator recording module includes indicator recording functions including 6 indicators of blood sugar, medication, diet, weight, exercise, and sleep. The main function of the indicator analysis module is to display the curve trends of the 6 indicators recorded by the patient in three days, one week, and one month. Comparing the change range of the mean value of glycosylated hemoglobin at the beginning and end of the two groups of patients, it can be found that the change range of glycosylated hemoglobin in the intervention group is −6.04%, while the change range of the control group is only −3.26%. The impact of the mobile medical app designed in this study will indeed be reflected in the patient's blood sugar control and help patients to better control blood sugar.
Collapse
|
2
|
Nie J. UNC0321 inhibits high glucose induced apoptosis in HUVEC by targeting Rab4. Biomed Pharmacother 2020; 131:110662. [PMID: 32877824 DOI: 10.1016/j.biopha.2020.110662] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 08/07/2020] [Accepted: 08/20/2020] [Indexed: 01/03/2023] Open
Abstract
The vascular complications in heart, brain, kidney and retina are the most common chronic complications of diabetes mellitus (DM). At present, it has become a research hotspot to regulate the abnormal apoptosis of vascular endothelial cells for DM treatment. UNC0321 is a high affinity GPCRs inhibitor, and has potential practical value in chromatin remodeling. In this study, we treated HUVEC with UNC0321 in vitro, and found that UNC0321 inhibit the level of Cleaved-Caspase3 and Bax, thus inhibiting the apoptosis caused by high glucose. In addition, UNC0321 also promoted cell proliferation and migration by activating Akt / mTOR pathway. The transcriptome changes of HUVEC cells cultured with high glucose with or without the treatment of UNC0321 were analysis using sequencing. It was found that Rab4 expression was significantly inhibited after UNC0321 treatment. Subsequently, we overexpressed Rab4 in HUVEC cells cultured with high glucose, and found that overexpression of Rab4 promoted the apoptosis, and inhibited cell proliferation and migration. At the same time, after overexpression of Rab4 in HUVEC cells treated with UNC0321, the number of apoptosis was significantly increased, cell proliferation and migration were inhibited, and the activity of Akt / mTOR pathway decreased. These data suggested that overexpression of Rab4 effectively blocked the inhibition of apoptosis and the increase of cell proliferation induced by UNC0321. In conclusion, we found that UNC0321 inhibits the apoptosis of HUVEC cells caused by high glucose through inhibiting Rab4 expression, providing new potential drugs and targets for the treatment of diabetic vascular complications.
Collapse
Affiliation(s)
- Jieming Nie
- Department of Internal Medicine, The Third Affiliated Hospital of Guangzhou Medical University, PR China.
| |
Collapse
|
3
|
Tang L, Li L, Yang J, Zeng C. Potential benefit of (-)-epigallocatechin-3-gallate for macrovascular complications in diabetes. ACTA ACUST UNITED AC 2017; 50:e6511. [PMID: 28832766 PMCID: PMC5561811 DOI: 10.1590/1414-431x20176511] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Accepted: 06/14/2017] [Indexed: 11/29/2022]
Abstract
Vascular problems are the most common complications in diabetes. Substantial evidence from epidemiological and pathophysiological studies show that hyperglycemia is a major risk factor for macrovascular complications in patients with diabetes. (-)-Epigallocatechin-3-gallate (EGCG), the major catechin derived from green tea, is known to exert a variety of cardiovascular beneficial effects. The protective effects of EGCG in diabetes are also evident. However, whether EGCG is beneficial against macrovascular complications that occur in diabetes remains unknown. Our previous studies demonstrated that treatment of EGCG inhibits high glucose-induced vascular smooth muscle cell proliferation and suppresses high glucose-mediated vascular inflammation in human umbilical vein endothelial cells. Therefore, we hypothesize that EGCG might be an effective potential candidate to reduce the macrovascular complications in diabetes.
Collapse
Affiliation(s)
- L Tang
- Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Institute of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Cardiovascular Clinical Research Center, Daping Hospital, Third Military Medical University, Chongqing, China
| | - L Li
- Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Institute of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Cardiovascular Clinical Research Center, Daping Hospital, Third Military Medical University, Chongqing, China
| | - J Yang
- Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Institute of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Cardiovascular Clinical Research Center, Daping Hospital, Third Military Medical University, Chongqing, China
| | - C Zeng
- Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Institute of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China.,Chongqing Cardiovascular Clinical Research Center, Daping Hospital, Third Military Medical University, Chongqing, China
| |
Collapse
|